← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › IMMUNE SERA AND IMMUNOGLOBULINS › IMMUNOGLOBULINS › Immunoglobulins, normal human
immunoglobulins, normal human, for intravascular adm.
J06BA02
Forms & Strengths
- lyophilized powder for reconstitution
- liquid solution
- concentrations: 1g/10mL, 5g/50mL, 10g/100mL
Adult Dosing
- dosage varies by indication and patient response
- typically 2g/kg as a single dose or divided over 2-5 days
- e.g. PID: 400mg/kg/day for 2-5 days
- e.g. Kawasaki disease: 2g/kg once
Pediatric Dosing
- dosage varies by indication and patient response
- typically 400mg/kg/day for 2-5 days for PID
- Kawasaki disease: 2g/kg once
Indications
- primary immunodeficiency diseases (PID)
- kawasaki disease
- chronic inflammatory demyelinating polyneuropathy (CIDP)
- immune thrombocytopenia purpura (ITP)
- guillain-barre syndrome
- multifocal motor neuropathy
Mechanism of Action
- replaces antibodies in immunodeficient patients
- modulates immune response
- neutralizes or removes pathogens, toxins, and inflammatory mediators
Contraindications
- history of anaphylactic or severe systemic reaction to human immunoglobulins
- selective IgA deficiency with known antibodies to IgA
Adverse Reactions
- infusion-related reactions (e.g. headache, fatigue, fever)
- thrombotic events
- hemolysis in patients with non-O blood group
- transfusion-related acute lung injury (TRALI)
- allergic reactions (e.g. rash, anaphylaxis)
Drug Interactions
- live vaccines: may interfere with immune response
- blood products: may increase risk of TRALI
Curated Content: Needs Vetting Before Put to Clinical Use